| DC46693 |
DAMGO
|
DAMGO (DAGO) is a potent and selective μ opioid receptor agonist with ki of 17 nM. |
| DC44976 |
LY2940094 tartrate
|
LY2940094 (BTRX-246040) tartrate is a potent, brain penetrant, selective and orally available N/OFQ peptide (NOP) receptor antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 tartrate reduces Ethanol self-administration and Ethanol seeking in animal models. |
| DC41767 |
Nociceptin(1-7) TFA
|
Nociceptin (1-7) TFA is the N-terminal bioactive fragment of nociceptin. Nociceptin (1-7) TFA is a potent ORL1 (NOP) receptor agonist with antinociceptive activity. Nociceptin (1-7) TFA combines with nociceptin reduces hyperalgesia in vivo.
|
| DC41766 |
Nociceptin(1-7)
|
Nociceptin (1-7) is the N-terminal bioactive fragment of nociceptin. Nociceptin (1-7) is a potent ORL1 (NOP) receptor agonist with antinociceptive activity. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia in vivo.
|
| DC40982 |
Loperamide phenyl
|
Loperamide phenyl is an impurity of Loperamide. Loperamide is an opioid receptor agonist.
|
| DC28780 |
LY2444296
|
LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ∼1 nM. LY2444296 exhibits anti-anxiety like effects. |
| DC10290 |
PZM21
|
PZM21 is a potent and selective μ opioid receptor agonist with an EC50 of 1.8 nM. |
| DC9527 |
Methylnaltrexone (Bromide)
|
Methylnaltrexone Bromide is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation.
|
| DC9526 |
Meptazinol (hydrochloride)
|
Meptazinol Hcl(WY-22811 Hcl) is a unique centrally active opioid analgesic.
|
| DC7050 |
ADL5859 HCl
|
ADL5859 agonizes δ-opioid receptor with a 1000-fold selectivity than µ- or κ-opioid receptor with Ki of 32 nM and 37 nM, respectively.ADL5859 displays weak inhibitory activity at the hERG channel with an IC50 of 78 μM. The EC50 of ADL5859 against δ opioid |
